A microdose clinical trial may be useful as a safe early-phase exploratory study using doses as low as 100 mg or less for determination of the disposition of a candidate compound in humans in a short period of time. This may increase conˆdence in candidate compounds, especially those for which it is di‹cult to predict disposition based on the results of in vitro or preclinical studies. In this study, we examined microdose trials performed in the preclinical stage for twoˆrst-in-class compounds with a new mechanism of action. These compounds showed species diŠerence inˆrst pass metabolism in the digestive tract and liver, causing uncertainty in prediction of disposition in humans. For this reason, rst-in-human microdose clinical trials were performed. The results showed that the two compounds had eŠective blood concentrations after oral administration at a dose of 100 mg qd. Administration of an extremely small dose of one 14 C-labeled compound permitted identiˆcation of major metabolites. No toxic metabolites were detected. The preclinical toxic dose was determined based on prediction of blood exposure at the estimated maximum clinical dose. For the other candidate compound, theˆndings of the microdose trial indicated a high bioavailability after oral administration and low hepatic clearance after intravenous administration. These results suggested only a small risk of a change in disposition in patients with hepatic disorder. The data obtained for the two compounds suggest that microdose clinical trials can be useful for improving the process of candidate selection in the preclinical stage. 
Data in rat, dog and monkey are shown as the mean in 3 subjects measured after oral administration at a dose of 1 mg/kg. Data in humans are shown based on prediction of the level at a dose of 1 mg/kg using preclinical data and as the mean in 8 subjects who received oral administration at a dose of 100 mg. 
